December 27, 2017 / 12:43 AM / 10 months ago

Appeals court denies Regeneron bid to revive patent case against Merus

A federal appeals court on Tuesday refused to reconsider its ruling that a patent Regeneron Pharmaceuticals Inc asserted against rival Merus NV is unenforceable because it was obtained through deception.

The U.S. Court of Appeals for the Federal Circuit denied a petition for en banc rehearing filed by Regeneron following a July 27 decision that found the Tarrytown, New York-based company obtained a patent relating to mice antibody technology by misleading the U.S. Patent and Trademark Office.

To read the full story on Westlaw Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below